TITLE

Possible Retroperitonel Fibrosis and Methysergide

AUTHOR(S)
Freestone, D. S.
PUB. DATE
May 1965
SOURCE
British Medical Journal;5/29/1965, Vol. 1 Issue 5447, p1434
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
64058951

 

Related Articles

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;2/5/2011, Issue 1337, p4 

    The article presents a study which examined retroperitoneal fibrosis associated with methysergide.

  • Methysergide-containing medicines: new restrictions.  // WHO Drug Information;2014, Vol. 28 Issue 1, p25 

    The article reports that the European Medicines Agency (EMA) has called for the restriction of the use of methysergide because of its association with fibrosis.

  • EMA restricts methysergide use, concern over fibrosis.  // Reactions Weekly;Mar2014, Vol. 1491 Issue 1, p2 

    The article reports on the recommendations of the European Medicines Agency (EMA) regarding the changes in the usage of methysergide due to concerns that the drug could cause fibrosis.

  • Retroperitoneal fibrosis associated with metoprolol. Thompson, J.; Julian, D.G. // British Medical Journal (Clinical Research Edition);1/9/1982, Vol. 284 Issue 6309, p83 

    Examines the association between retroperitoneal fibrosis and metoprolol. Recognition of analgesic abuse and methysergide as etiological agents; Relationship between the incidence of retroperitoneal fibrosis in the middle-aged; Significance of the results on the mucocutaneous syndrome...

  • METHYSERGIDE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p546 

    This article presents information on methysergide, an vasoconstrictor, including dosage, usage, adverse reactions, side effects and possible interaction with other drugs.

  • Methysergide and retroperitoneal fibrosis.  // Australian Prescriber;Feb2011, Vol. 34 Issue 1, p24 

    Retroperitoneal fibrosis is a well recognised adverse effect associated with long-term uninterrupted use of methysergide. To reduce the risk of this adverse effect, withdraw methysergide for 3 to 4 weeks at least every 6 months. Reduce the dose gradually during the last 2 to 3 weeks of each...

  • retroperitoneal fibrosis.  // Taber's Cyclopedic Medical Dictionary;2005, p1903 

    A definition of the term "retroperitoneal fibrosis" is presented. It refers to the development of a mass of scar tissue in the retroperitoneal space. This disease may be associated with taking methysergide for migraine, and with other drugs. It causes physical compression of the ureters, vena...

  • Methysergide and retroperitoneal fibrosis.  // WHO Drug Information;2011, Vol. 25 Issue 1, p28 

    The article discusses cases of retroperitoneal fibrosis which have been reported in Australia in connection with long term use of the ergot alkaloid methysergide, which is used to treat several types of headaches including migraines and cluster head aches.

  • METHYSERGIDE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p548 

    The article presents information on methysergide, a vasoconstrictor drug, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • METHYSERGIDE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p546 

    The article presents information on methysergide, a vasoconstrictor drug, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics